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Abstract
Fabry disease, a rare, X-linked lysosomal storage disease, arises from deficiency of the lysosomal 
hydrolase, α-galactosidase A (GLA) which disrupts the catabolism of globo-series 
glycosphingolipids (GSLs). One potential link between GLA deficiency and vascular dysfunction 
may be changes in endothelial nitric oxide synthase (eNOS) function. GLA-deficient EA.hy926 
cells were obtained by siRNA knockdown of GLA expression and by mutation of GLA with 
CRISPR/Cas9 gene editing to investigate the effects of GLA deficiency on eNOS. As previously 
observed with siRNA knockdown of GLA, globotriaosylceramide (Gb3) accumulated in 
EA.hy926 cells. In contrast, Gb3 did not accumulate in CRISPR/Cas9 gene edited GLA-deficient 
cells, but instead, globotetraosylceramide (Gb4). However, in both the siRNA and CRISPR/Cas9 
models globotriaosylsphingosine (lyso-Gb3) was elevated. As was previously observed with 
siRNA knockdown of GLA expression, CRISPR/Cas9 GLA-deficient cells had lower eNOS 
activity. Restoring GLA activity in GLA-deficient cells with exogenous GLA treatment improved 
eNOS activity. In contrast, treating cells with the glucosylceramide synthase inhibitor, eliglustat, 
decreased NOS activity. These results suggest that eNOS uncoupling is due to GLA deficiency, 
and not necessarily due to elevated Gb3 per se. It was observed that lyso-Gb3 inhibits eNOS 
activity.
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1. Introduction
Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA 
gene. Fabry disease affects multiple organs and gives rise to a variety of complications, 
including kidney failure, neuropathy, and cardiovascular and cerebrovascular events (Eng, 
Fletcher et al. 2007). Deficient α-galactosidase A (GLA) activity results in elevated levels of 
glycosphingolipids (GSLs) with terminal α−1,4-galactose groups. These globo-series GSLs 
accumulate in various cells and tissues, but are particularly prominent in vascular tissues and 
more specifically in endothelial cells (Linhart and Elliott 2007). In clinical and laboratory 
studies the primary GSL observed to accumulate in tissues is globotriaosylceramide (Gb3), a 
primary substrate for GLA. However, plasma Gb3 is not a reliable biomarker for individual 
symptoms (Vedder, Linthorst et al. 2007). Globotriaosylsphingosine (lyso-Gb3), the 
deacylated metabolite of Gb3, may better correlate with symptoms, especially in 
symptomatic heterozygous females with the disease (Aerts, Groener et al. 2008).
Impaired endothelial nitric oxide synthase (eNOS) activity has been observed in several 
experimental models of Fabry disease. This impairment is manifest as both decreased NO 
availability and eNOS uncoupling (Eitzman, Bodary et al. 2003, Bodary, Shen et al. 2005, 
Park, Whitesall et al. 2008, Shu, Park et al. 2009, Shu, Vivekanandan-Giri et al. 2014). 
Decreased NO bioavailability is associated with the loss of normal vasodilation in arterial 
vessels. eNOS uncoupling occurs when there is improper flow of electrons from the 
reductase domain of eNOS, to the oxygenase domain, which results in formation of O2− 
instead of NO (Vasquez-Vivar, Kalyanaraman et al. 1998, Xia, Tsai et al. 1998). O2− can 
then react with NO to produce a reactive nitrogen species, peroxynitrite (ONOO−). ONOO− 
can then rapidly oxidize a cofactor of eNOS, tetrahydrobiopterin (BH4), to the inactive 
form, dihydrobiopterin (BH2), which causes further uncoupling (Milstien and Katusic 
1999). A biomarker for ONOO−, 3-nitrotyrosine, which results from protein nitrosylation 
(Heinecke 2002), was found to be elevated in the plasma of Fabry patients (Shu, 
Vivekanandan-Giri et al. 2014). The mechanism by which GLA deficiency causes eNOS 
uncoupling has not been well elucidated.
Previous in vitro models of Fabry disease our group has utilized mouse aortic endothelial 
cells (MAECs) from Gla-knockout mice, and the human endothelial cell line, EA.hy926 
with anti-GLA siRNA treatment (Shu and Shayman 2007, Shu, Vivekanandan-Giri et al. 
2014). Both models have provided insight into how GLA-deficiency affects GSL 
accumulation in the cell and affects eNOS function. However, each has its limitations. 
MAECs are challenging to maintain in culture, and in anti-GLA siRNA-treated EA.hy926 
cells the GLA depletion is not sustained for longer than the duration of the siRNA treatment 
(3–6 days). In this study, cell lines with a permanent absence of GLA protein expression 
were developed to be able to study eNOS uncoupling in the setting of GLA deficiency. 
These cells were obtained by using the CRISPR/Cas9 method of gene editing.
We report the surprising finding that CRISPR/Cas9 gene edited EA.hy926 cells displaying a 
permanent absence of GLA expression did not accumulate Gb3 in contrast to EA.hy926 
cells treated with anti-GLA siRNA. However, both models of GLA-deficient EA.hy926 cells 
showed loss of eNOS activity.
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2. Material and methods
2.1. Cell culture
EA.hy926 cells (ATCC, Manassas, VA) were maintained at 37 °C with 95/5 O2/CO2, in 
DMEM/F-12, GlutaMAX (Thermo Fisher Scientific, Waltham, MA) supplemented with 
heat-inactivated 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL 
streptomycin, which will be later referred to as “growth medium.”
2.2. CRISPR/Cas9 plasmid generation and delivery
In order to disrupt GLA expression in EA.hy926 cells, single-stranded guide RNA was 
designed to target Exon 1 of Gla using the Optimized Design Tool (crispr.mit.edu). The 
forward primer was ATTGGCAAGGACGCCTACCA (GTTTT), and the reverse primer was 
TGGTAGGCGTCCTTGCCAAT (CGGTG). The parentheses indicate sequence 
complementary to the 3’ overhang sequence in the CRISPR nuclease vector. Forward and 
reverse single-stranded oligonucleotides were annealed to generate a double-stranded 
oligonucleotide. The oligonucleotide was cloned into the GeneArt CRISPR nuclease vector 
(Thermo Fisher Scientific), which expresses the orange florescence protein (OFP) reporter. 
The vector was transformed into One Shot TOP10 E. coli cells (Thermo Fisher Scientific). 
Bacteria were grown on LB agar plates with ampicillin and incubated at 37 °C overnight. 
Clones were selected and grown in LB broth overnight. Plasmids were purified and 
sequenced with the U6 forward primer to verify the presence and proper orientation of 
double-stranded oligonucleotide.
EA.hy926 cells were plated at 600,000 cells/well on six-well dishes. The following day, 2 µg 
of CRISPR plasmid DNA was transfected using Lipofectamine 3000 (Thermo Fisher 
Scientific), and incubated with DMEM-F12 GlutaMAX™ supplemented with 10% FBS for 
24 hours. Cells were FACS sorted on a BD FACSAria™ II flow cytometer (BD Biosciences, 
San Jose, CA) with BD FACSDiva 8.0 software. OFP positive cells were collected and 
plated onto 150 mm dishes at low density in normal growth conditions. Cells were allowed 
to grow for several days, and then cloning cylinders were used to isolate individual colonies. 
Cells were grown in the same media conditions described for EA.hy926 cells.
2.3. siRNA silencing of GLA in EA.hy926 cells
The transfection of EA.hy926 cells was performed as previously described, but with minor 
modification (Shu, Vivekanandan-Giri et al. 2014). For cells that were to be harvested after a 
single transfection, the following protocol was observed. One day before transfection, 0.8 × 
106 cells were seeded onto 150 mm cell culture dishes with growth medium. At the time of 
transfection (day 0), growth medium was replaced with Opti-MEM-I (Thermo Fisher 
Scientific). Next, anti-GLA siRNA or scrambled-siRNA control (scr-siRNA) was mixed 
with Lipofectamine RNAiMax (Thermo Fisher Scientific) according to the manufacturer’s 
protocol. After 8 hours, the medium was replaced with growth medium. Cells were 
harvested on day 1 or 3 post-transfection.
For cells that were to be harvested after a double transfection, the following protocol was 
observed. One day before transfection, 0.7 × 106 cells were seeded onto 150 mm cell culture 
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dishes with growth medium. The same 3-day transfection protocol was followed as 
described above, but instead of harvesting the cells on day 3, cells were transfected once 
more with the same treatment, and later harvested on day 6.
2.4. Western blotting
Colonies that were identified as having a mutation were grown to confluency on 100 mm 
dishes. Cells were harvested with 0.05% trypsin-EDTA and lysed in a buffer consisting of 25 
mM Tris-HCl, 137 mM NaCl, 2 mM EDTA, 2 mM Na3VO4, 20 mM NaF, 1% Triton X-100, 
10% glycerol, and protease inhibitor (P8340, Sigma). Cells were probe sonicated on ice and 
centrifuged at 10,000 x g for 10 minutes at 4 °C. Supernatants were saved and total cellular 
protein determined with bicinchoninic acid (BCA) assay using bovine serum album (BSA) 
as a standard (Pierce BCA Protein Assay Kit, Thermo Fisher Scientific). Thirty μg of protein 
were denatured with 2-mercaptoethanol in Laemmli buffer, heated at 95 °C for 10 minutes, 
and then separated on NuPAGE 4–12% SDS-PAGE (Thermo Fisher Scientific). Proteins 
were transferred to nitrocellulose membranes, blocked for 1 hour with 5% nonfat dry milk-
TBST (tris-buffered saline, tween-20), then incubated with primary antibody against GLA 
(1:1000 in 5% milk-TBST, EPR5829, (ab129173) Abcam, Cambridge MA), eNOS (1:1000 
in 5% nonfat dry milk-TBST, M221 (ab76198) Abcam), or GAPDH (1:1000 in 1% BSA-
TBST, #MAB374, EMD Millipore, Billerica, MA) overnight at 4 °C. After washing with 
TBST, membranes were incubated with anti-mouse (for eNOS and GAPDH detection) or 
anti-rabbit (for GLA detection) secondary antibody at (1:15,000 in 1% BSA-TBST). 
Membranes were washed with TBST and incubated with enhanced chemiluminescence 
(Pierce ECL Western Blotting Substrate, Thermo Fisher Scientific). Protein bands were 
detected with film exposure. The film was scanned and protein bands quantified with ImageJ 
Software.
2.5. Lipid extraction
Cells were grown to confluency on 150 mm cell culture dishes and harvested by scraping 
into 700 μL PBS. The cell suspension was transferred into 16 mm × 100 mm glass tubes, 
and 1 mL chloroform and 2.4 mL methanol were added. After water bath sonication, cell 
protein was precipitated by centrifuging at 2400 × g for 30 minutes. The supernatant was 
transferred to a new glass tube and 4.5 mL chloroform and 1.2 mL 0.9% NaCl were added. 
The sample was centrifuged at 900 × g for 5 minutes. The upper aqueous phase was 
discarded, and the lower organic phase was washed twice with 2 mL methanol and 0.8 mL 
0.9% NaCl. The lower phase was extracted using a 1 mL glass syringe (Hamilton, Reno, 
NV) and transferred to a new glass tube. Lipids were dried under a stream of nitrogen.
2.6. Total phospholipid assay
Total phospholipid was determined as follows (Ames 1966). Dried lipids were suspended in 
500 μL of chloroform/methanol (2:1, v/v). Thirty μL of sample was transferred to 13 × 100 
mm glass tube, and 30 μL of 10% Mg(NO3)2.6H2O in 95% EtOH was added. The mixture 
was dried under a stream of nitrogen and ashed for 30 seconds over a flame. After cooling to 
room temperature, 300 μl of 0.5 M HCl was added and incubated at room temperature for 30 
minutes. Then, 700 µL of (1:6, v/v) 10% ascorbic acid: 0.42% (NH4)2Mb·4H2O was added 
and samples and standards were incubated for 45 minutes at 45 °C. Samples were cooled to 
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room temperature and absorbance measured at 820 nm. Samples were compared to 
standards of 0, 5, 10, 20, 30, 40 µL of 1 mM KH2PO4, that were prepared simultaneously. 
Total phospholipid was calculated according to the standard curve. The volume according to 
100 nmol of total phospholipid was transferred to a new glass tube and dried under a stream 
of nitrogen.
2.7. Alkaline methanolysis and acid hydrolysis
Two mL chloroform and 1 mL 0.21 M NaOH in 100% methanol were added to the dried 
lipids. Samples were incubated at room temperature for 1 hour. The reaction was terminated 
by addition of 0.8 mL 0.25 M HCl and centrifuged at 900 × g for 5 minutes. The upper 
aqueous phase was removed and lower organic phase was transferred with a 1 mL Hamilton 
syringe to a new 16 mm × 125 mm glass tube. Four mL methanol and 1.6 mL 0.05 M 
HCl/25 mM HgCl2 were added. The mixture was incubated at 37 °C for 15 minutes. Two 
mL of chloroform and 1.6 mL of water was added. Samples were centrifuged at 900 × g for 
5 minutes. The upper aqueous phase was removed and 2 mL methanol and 1 mL 30 mM 
EDTA pH 8.0 were added to the lower organic phase. Samples were centrifuged and the 
upper phase was removed again. The lower organic phase was washed twice with 2 mL 
methanol and 1.6 mL water. The lower layer was transferred with a 1 mL glass syringe to a 
new 12 × 100 mm glass tube and dried under a stream of nitrogen.
2.8. Thin layer chromatography – LacCer, Gb3, and Gb4 measurements
One hundred nmol of total phospholipid was applied to a silica high performance TLC plate 
(Sigma-Aldrich). The plate was first developed in a solvent system consisting of chloroform/
methanol (98:2, v/v), and air dried. The plate was then developed in a solvent system 
consisting of chloroform/methanol/acetic acid/water (61/31/5/3, v/v/v/v) and air dried. Plates 
were sprayed with 1% orcinol in 11% H2SO4 and charred at 130 °C for 5 minutes. Plates 
were scanned and densitometry measured using ImageJ software. Lipids were quantified by 
running glucosylceramide (GlcCer), lactosylceramide (LacCer), globotriaosylceramide 
(Gb3), and globotetraosylceramide (Gb4) standards on each plate (Matreya LLC, State 
College, PA).
2.9. Exogenous GLA treatment
Cells (1.0 × 106) were seeded on 150 mm cell culture dishes with growth medium. The 
following day, growth medium was replaced with fresh media, and 3 U of α-galactosidase A 
(Green coffee bean extract, Sigma), was added. Cells grew for 3 days and were harvested for 
lipid analysis with TLC. This dose was chosen based on a previous study using 10 μg/mL 
GLA to treat cells (Shu and Shayman 2007).
2.10. Eliglustat treatment
Cells (1.0 × 106) were seeded on 150 mm cell culture dishes with DMEM/F12 GlutaMAX 
supplemented with 5% FBS. The following day, medium was replaced with DMEM/F12 
GlutaMAX supplemented with 2% FBS. Cells were treated with either PBS vehicle control, 
20 or 200 nM eliglustat. Cells were harvested 3 days later for lipid analysis with TLC.
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2.11. NOS activity measurement
Endothelial nitric oxide synthase (eNOS) activity in EA.hy926 cell lysates was analyzed by 
using a NOS activity assay kit (Cayman Chemical, Ann Arbor, MI) according to the 
manufacturer’s instructions. This assay measures the biochemical conversion of L-arginine 
to L-citrulline by NOS. Cells were harvested with 0.05% trypsin-EDTA and washed with 
PBS two times. Cell pellets were lysed in the provided homogenization buffer (final 
concentration 1 mM EDTA and 1 mM EGTA in 25 mM Tris-HCl (pH 7.4) buffer). After 
brief sonication, samples were centrifuged at 12,000 × g for 5 minutes, and supernatants 
transferred to new tubes. Cell lysates (5 µL) were incubated at room temperature for 3 hours 
with 1 µCi [3H]L-arginine (PerkinElmer), 100 nM calmodulin, and the provided reaction 
buffer (final concentration 1 mM NADPH, 600 µM CaCl2, 25 mM Tris-HCl (pH 7.4), 3 µM 
tetrahydrobiopterin, 1 µM flavin adenine dinucleotide, and 1 µM flavin adenine 
mononucleotide in 50 µL). The reaction was stopped by adding 400 µL of 5 mM EDTA in 
50 mM HEPES (pH 5.5) buffer. The provided resin was added to each sample to remove 
[3H]L-arginine. Radioactivity due to [3H]L-citrulline was measured as counts per minute 
(cpm) using a scintillation counter. Cpm were also measured in samples with no cell lysate 
as a background control. NOS activity of each sample was calculated by subtracting 
background cpm from the cpm for each sample, and then normalizing to total protein in each 
5 µL sample, determined by the BCA protein assay. In some experiments 
glucosylsphingosine (GlcSph) or globotriaosylsphingosine (lyso-Gb3) (Matreya) were added 
to each reaction for a final concentration of 0 – 60 μM.
2.12. Lyso-Gb3 measurements
To measure lyso-Gb3 in EA.hy926-CRISPR/Cas9 clonal cell lines, 0.7 × 106 cells were 
seeded on 100 mm dishes. The following day, media was replaced with fresh growth media. 
Three days later, media was collected and cells harvested with 0.05% trypsin-EDTA. Cells 
and media were collected the same way in siRNA-treated EA.hy926 cells with the 
transfection method described above. Cell pellets were sonicated on ice in 200–250 μL PBS, 
centrifuged at 12,000 × g, and supernatant collected. BCA protein assay was performed. 
Lyso-Gb3 was measured with as previously described (Gold, Mirzaian et al. 2013). Results 
were normalized to protein concentration.
2.13. Statistical analysis
Data were analyzed by using Prism 7.0 software (GraphPad Software Inc., La Jolla, CA). 
Significance was determined by two-way analysis of variance (ANOVA) with Dunnett’s or 
Sidak’s multiple comparisons test. Values are shown as mean ± SEM. Differences between 
groups were considered statistically significant at a P-value of <0.05.
3. Results
3.1. GLA-deficient cells accumulate Gb4
Gla-deficient clonal cell lines were obtained by CRISPR/Cas9 gene editing, and the absence 
of Gla expression was confirmed by Western blot (figure 1a) and GLA enzyme assay (figure 
S.1). DNA sequencing confirmed a single base pair deletion in the targeted region of Gla 
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(figure S.2). To determine the effect of GLA deficiency on globo-series GSL accumulation, 
whole cell lipids were isolated and separated by thin layer chromatography (figure 1b). 
Globo-series GSLs was detected by staining with 1% orcinol (w/v) solution in 11% H2SO4 
(v/v). Cell lysates from GLA-deficient cells have a 2.5 to 4-fold higher amount of Gb4 
content over the WT cell line (figure 1c). Only one clonal cell line had an increase in Gb3, 
the primary substrate for GLA (figure 1d). This is in contrast to a previous study that used 
EA.hy926 cells treated with anti-GLA siRNA for 3 or 6 days, which resulted in Gb3 
accumulation (Shu, Vivekanandan-Giri et al. 2014). In light of the prevalence of Gb4 instead 
of Gb3 in the CRISPR/Cas9 GLA-deficient EA.hy926 cells, Gb4 content in anti-Gla siRNA 
– treated EA.hy926 cells was also measured. Anti-GLA siRNA treatment completely 
knocked down Gla expression (figure S.3), and increased Gb4 by 35% compared to 
scrambled siRNA treatment (figure S.4). LacCer accumulation is also different between the 
CRISPR/Cas9 and siRNA models. CRISPR/Cas9 Gla-deficient cells have a decrease in 
LacCer (figure 1e), whereas cells treated with anti-Gla siRNA have an increase in LacCer 
content (figure S.4).
3.2. Lyso-Gb3 is elevated in both GLA-siRNA knockdown and CRISPR/Cas9 GLA-
deficient cells
Because the correlation between GLA deficiency and Gb3 or Gb4 content differed between 
the CRISPR/Cas9 and siRNA models of GLA in EA.hy926 cells, the levels of lyso-Gb3 in 
the two models were assessed. Cell lysates from CRISPR/Cas9 GLA-deficient clonal cell 
lines had a 3 to 4-fold increase of lyso-Gb3 compared to WT control (figure 2a). Similarly, 
6-day treatment of anti-GLA siRNA in EA.hy926 cells caused a significant increase of lyso-
Gb3 compared to scr-siRNA control and 3-day anti-GLA siRNA treated cells (figure 2b). In 
contrast to LacCer, Gb3, and Gb4, lyso-Gb3 is a marker that is consistently elevated in both 
siRNA and CRISPR/Cas9 models of GLA deficiency in EA.hy926 cells.
3.3. Decreased NO production and eNOS expression in GLA-deficient cells
Three of the four GLA-deficient cell lines had 40–50% of NOS activity compared to WT 
cells (figure 3a). One GLA-deficient cell line, clone 2, had a 14% reduction of NOS activity 
compared to WT. To verify [3H]L-citrulline that was measured in the NOS activity assay 
originated from NOS activity, reactions were repeated with the addition of a competitive 
NOS inhibitor, NG-nitro-L-arginine (L-NNA) to the NOS reaction mixture. There was no 
detectable [3H]L-citrulline above background with L-NNA (data not shown).
A possible reason for decreased NOS activity is reduced eNOS expression. A Western blot 
was performed to detect eNOS expression in WT and GLA-deficient cells (figure 3b). 
Although there is a trend of decreased eNOS expression in GLA-deficient cells that 
correlates with decreased NOS activity, the change was not statistically significant (p=0.08 
for clone 12 compared with 17(WT)).
3.4. Two methods of reducing neutral GSLs have different effects on NOS activity
Two pharmacological approaches were used to determine if diminished NOS activity is due 
to the absence of functional GLA or accumulation of globo-series GSLs. Cells were treated 
for three days with either exogenous GLA, which primarily decreases Gb3 levels (figure S.
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5), or eliglustat (20 or 200 nM), which decreases globo-series GSLs (figure S.6) due to the 
inhibition of glucosylceramide synthase. GLA enzyme treatment increased NOS activity in 
all cells (figure 4a), indicating a direct correlation between the presence of the functional 
GLA enzyme and functioning NOS. In contrast, eliglustat treatment decreased NOS activity 
in a dose-dependent manner (figure 4b), suggesting that decreasing all globo-series GSLs 
decreases NOS activity. The level of lyso-Gb3 in cell lysates after treatment with eliglustat 
or exogenous GLA was not measured.
3.5. Lyso-Gb3 inhibits NOS activity
We previously determined that GLA-deficient EA.hy926 cells have elevated 
globotriaosylsphingosine (lyso-Gb3) compared to WT cells (figure 2). GLA-deficient cells 
were also shown to have decreased NOS activity (figure 3a). To determine if there is a 
correlation between presence of lyso-Gb3 and NOS activity, lyso-Gb3 (250 or 500 nM) was 
added to cell culture media for three days, and NOS activity was measured in cell lysates. 
The concentrations used are within the range reported to increase smooth muscle cell 
proliferation (Aerts, Groener et al. 2008). However, there was no change in NOS activity 
compared to cells treated with DMSO or glucosylsphingosine (GlcSph) (data not shown).
To directly assess the effect of lyso-Gb3 on eNOS, lyso-Gb3 or GlcSph were added to the 
NOS reaction mixture to achieve a final concentration of 0 – 60 μM lyso-Gb3 or GlcSph in 
each reaction volume. NOS activity was measured in the GLA-deficient clonal cell line 12, 
and wild type cell line 17. Lyso-Gb3 inhibited the NOS reaction in a dose-dependent manner 
(figure 5a). GlcSph also decreases NOS activity, but at a higher dose (figure 5b). These 
effects on NOS activity were observed in both WT and GLA-deficient cells.
4. Discussion
In this study, we developed cell lines that are GLA-deficient to investigate the effect of 
specific changes in globo-series GSLs on eNOS activity. In contrast to other in vitro models 
of Fabry disease, these cells do not accumulate Gb3, the primary substrate for GLA, but still 
exhibit less NOS activity. Consistent with other Fabry disease models and clinical data, these 
cells had elevated lyso-Gb3 content. Furthermore, two pharmacological approaches of 
decreasing globo-series GSLs have opposite effects on NOS activity, suggesting restoring 
GLA function is better for improving NO production and reversing eNOS uncoupling than is 
reducing GSL accumulation. The relative changes in the globo-series glycolipids and their 
association with eNOS activity is shown in table 1.
Patients with Fabry disease have an increased incidence of vasculopathy compared to the 
non-Fabry population (Sims, Politei et al. 2009). GLA deficiency causes accumulation of 
globo series GSLs, most notably in vascular endothelial cells (Desnick, Ioannou et al. 2001). 
Past studies indicate that defects of vascular dysfunction can be localized to the 
endothelium, and eNOS uncoupling may be the basis for impaired vascular function (Shu, 
Park et al. 2009, Shu, Vivekanandan-Giri et al. 2014). In the microvasculature, eNOS 
uncoupling may be a factor in gastrointestinal complications seen in patients with Fabry 
disease (Kang, Shu et al. 2014). To further investigate biochemical changes in endothelial 
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cells due to GLA deficiency, we used the CRISPR/Cas9 method of gene editing to obtain 
permanent cell lines that were GLA deficient.
Previously, our group used primary cells isolated from mouse aortas of GLA knockout mice 
(mouse aortic endothelial cells, MAECs), which were useful for characterizing lipid changes 
and efficacy of GlcCer synthase inhibition for decreasing accumulating Gb3 (Shu, Murphy 
et al. 2005). However, this model was not sustainable for studying long-term consequences 
of treating cells with different agents since these cells could only be maintained in cell 
culture for a limited time (3 to 6 days). The anti-GLA siRNA EA.hy926 cell model was 
useful for making initial observations of how GLA-deficiency affects NOS activity, even 
when GLA was absent for only a few days, and for identifying 3-nitrotyrosine (a marker of 
eNOS uncoupling (Heinecke 2002)) as a biomarker for GLA deficiency (Shu, 
Vivekanandan-Giri et al. 2014). However, similar to MAECs, this in vitro model is not 
sustainable because a single siRNA treatment lasts for only three days. There can also be 
off-target effects of the siRNA.
An advantage of the CRISPR/Cas9 GLA-deficient cell model is that they can be continually 
passaged and retain the GLA-deficient characteristic with no additional treatment. To 
account for off-target effects of the initial CRISPR/Cas9 transfection, multiple single cell 
colonies were isolated, grown, and analyzed. While the measurements of Gb3, Gb4, and 
NOS activity were variable (figures 1 and 3), the lyso-Gb3 levels were consistently elevated 
in all four GLA-deficient clonal cell lines (figure 2). Potential off-target effects of the 
CRISPR/Cas9 transfection are unknown, but may have contributed to this observation. 
Moreover, the differences seen between the CRISPR/Cas9 and siRNA models of GLA 
depletion may be due to adaptive changes taking place in the CRISPR/Cas9 treated cells 
because they are continually passaged and have been without GLA expression for a longer 
period time than the cells treated with siRNA. The variation in Gb3 accumulation could be 
due to changes in Gb3 synthesis, or degradation to lyso-Gb3.
Despite differences of Gb3 and Gb4 accumulation, both the CRISPR/Cas9 and siRNA 
models of GLA deficiency in EA.hy926 cells have decreased NOS activity (figure 3 and 
(Shu, Vivekanandan-Giri et al. 2014)) and elevated lyso-Gb3 (figure 2). Lyso-Gb3, a 
deacylated form of Gb3, has emerged as a biomarker for Fabry disease (Aerts, Groener et al. 
2008). Lyso-Gb3 is elevated in plasma from Fabry patients and in GLA-deficient mice. 
Lyso-Gb3 levels go down post-enzyme replacement therapy (ERT) (van Breemen, Rombach 
et al. 2011). Furthermore, lyso-Gb3 is useful for monitoring Fabry disease in females. 
Heterozygous females have normal circulating levels of GLA and Gb3, but may still 
experience symptoms of the disease. Symptomatic heterozygous females have elevated 
plasma lyso-Gb3, while lyso-Gb3 cannot be detected in asymptomatic heterozygous females 
(Aerts, Groener et al. 2008, Rombach, Dekker et al. 2010, Togawa, Kodama et al. 2010, 
Smid, van der Tol et al. 2015). In our study, Gb3 was not consistently elevated in all GLA-
deficient clonal cell lines, but lyso-Gb3 was.
Lyso-lipids found to be elevated in other lipid storage diseases, for example, Krabbe disease 
(galactosylsphingosine), and Gaucher disease (glucosylsphingosine), have been shown to 
have toxic effects (Tanaka and Webster 1993, Schueler, Kolter et al. 2003). Lyso-Gb3 has 
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also been shown to be involved in the pathogenesis of Fabry disease. Lyso-Gb3, but not Gb3 
or lactosylsphingosine, promotes smooth muscle cell proliferation, which may contribute to 
the increased intima-media thickening seen in patients (Aerts, Groener et al. 2008). Lyso-
Gb3 induces podocyte injury, which is an early feature of Fabry nephropathy (Sanchez-
Nino, Sanz et al. 2011). In the present study, when cells were treated with physiologically 
relevant doses of lyso-Gb3, there were no observed changes in NOS activity in cell lysates. 
It is unknown if lyso-Gb3 in the cell culture medium was able to get into cells and affect 
intracellular lyso-Gb3 content. However, lyso-Gb3 was found to inhibit NOS when added to 
cell lysates (figure 5), but further work needs to be done to determine the mechanism of 
interaction. The concentration of lyso-Gb3 that inhibits NOS in this in vitro experiment is 
higher than that observed in the plasma of Fabry patients. Considering that eNOS is 
localized to the caveolae in the plasma membrane (Shaul, Smart et al. 1996), further studies 
need to be done to assess if lyso-Gb3 is also found at the plasma membrane, and if the 
concentrations of lyso-Gb3 used in these experiments are physiologically relevant.
The primary treatment method for Fabry disease is enzyme replacement therapy (ERT) with 
recombinant GLA. Substrate deprivation is an alternative approach to reducing accumulation 
of globo-series GSLs, where a small molecule inhibitor of glucosylceramide (GlcCer) 
synthase prevents the de novo synthesis of downstream GSLs, including LacCer, Gb3, and 
Gb4 (Abe, Arend et al. 2000, Abe, Gregory et al. 2000). A previous in vitro experiment 
performed with MAECs from Gla-knockout mice reported that treating cells with 
recombinant GLA or a GlcCer synthase inhibitor reduced the accumulation of Gb3 (Shu, 
Murphy et al. 2005). Similarly, treating CRISPR/Cas9 GLA-deficient EA.hy926 cells with 
exogenous GLA or the GlcCer inhibitor, eliglustat, decreased the accumulation of globo-
series GSLs (figs. S.5 and S.6). Eliglustat treatment decreases NOS activity, even in WT 
cells (figure 4b). These results are in agreement with a previous study where treatment of 
MAECs from Gla-deficient mice with the GlcCer synthase inhibitor, D-threo-
ethylenedioxyphenyl-2-palmitoylamino-3-pyrrolidinopropanol (P4), did not improve NOS 
activity, although Gb3 was cleared from cells (Shu, Park et al. 2009). In contrast, treating 
EA.hy926 cells with exogenous GLA increased NOS activity, in both GLA-deficient and 
WT cells (figure 4A). The opposite effects of two methods of reducing GSLs on NOS 
activity suggests that restoring GLA activity, rather than decreasing GSL content, may be 
more important for improving NOS activity.
5. Conclusion
eNOS uncoupling, observed in in vivo models of Fabry disease, is also observed in the 
CRISPR/Cas9 GLA-deficient EA.hy926 GLA-deficient endothelial cells. However, eNOS 
uncoupling tracks with increased lyso-Gb3 and is not necessarily the result of elevated Gb3 
per se.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Kaissarian et al. Page 10
Mol Genet Metab. Author manuscript; available in PMC 2019 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Acknowledgments
This work was supported by NIH grant RO1 DK 055823.
References
Abe A, Arend LJ, Lee L, Lingwood C, Brady RO and Shayman JA (2000). “Glycosphingolipid 
depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase.” 
Kidney Int 57(2): 446–454. [PubMed: 10652021] 
Abe A, Gregory S, Lee L, Killen PD, Brady RO, Kulkarni A and Shayman JA (2000). “Reduction of 
globotriaosylceramide in Fabry disease mice by substrate deprivation.” J Clin Invest 105(11): 1563–
1571. [PubMed: 10841515] 
Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, 
Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, 
Boot RG, Hollak CE, Brady RO and Poorthuis BJ (2008). “Elevated globotriaosylsphingosine is a 
hallmark of Fabry disease.” Proc Natl Acad Sci U S A 105(8): 2812–2817. [PubMed: 18287059] 
Ames BN (1966). “[10] Assay of inorganic phosphate, total phosphate and phosphatases.” Methods in 
Enzymology 8: 115–118.
Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, Gu S, Shayman JA and Eitzman DT (2005). 
“Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E 
deficiency.” Circulation 111(5): 629–632. [PubMed: 15668341] 
Desnick RJ, Ioannou YA and Eng CM (2001). “α-Galactosidase A deficiency: Fabry disease.” The 
Metabolic and Molecular Bases of Inherited Disease(136): 3733–3774.
Eitzman DT, Bodary PF, Shen Y, Khairallah CG, Wild SR, Abe A, Shaffer-Hartman J and Shayman JA 
(2003). “Fabry disease in mice is associated with age-dependent susceptibility to vascular 
thrombosis.” J Am Soc Nephrol 14(2): 298–302. [PubMed: 12538729] 
Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain 
DP, Nicholls K and Banikazemi M (2007). “Fabry disease: baseline medical characteristics of a 
cohort of 1765 males and females in the Fabry Registry.” J Inherit Metab Dis 30(2): 184–192 
[PubMed: 17347915] 
Gold H, Mirzaian M, Dekker N, Joao Ferraz M, Lugtenburg J, Codee JD, van der Marel GA, 
Overkleeft HS, Linthorst GE, Groener JE, Aerts JM and Poorthuis BJ (2013). “Quantification of 
globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance 
liquid chromatography-tandem mass spectrometry.” Clin Chem 59(3): 547–556. [PubMed: 
23237761] 
Heinecke JW (2002). “Oxidized amino acids: culprits in human atherosclerosis and indicators of 
oxidative stress.” Free Radic Biol Med 32(11): 1090–1101. [PubMed: 12031894] 
Linhart A and Elliott PM (2007). “The heart in Anderson-Fabry disease and other lysosomal storage 
disorders.” Heart 93(4): 528–535. [PubMed: 17401074] 
Milstien S and Katusic Z (1999). “Oxidation of tetrahydrobiopterin by peroxynitrite: implications for 
vascular endothelial function.” Biochem Biophys Res Commun 263(3): 681–684. [PubMed: 
10512739] 
Kang JJ, Shu L, Park JL, Shayman JA and Bodary PF (2014). “Endothelial nitric oxide synthase 
uncoupling and microvascular dysfunction in the mesentery of mice deficient in alpha-
galactosidase A.” Am J Physiol Gastrointest Liver Physiol 306(2): G140–146. [PubMed: 
24232002] 
Park JL, Whitesall SE, D’Alecy LG, Shu L and Shayman JA (2008). “Vascular dysfunction in the 
alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect.” 
Clin Exp Pharmacol Physiol 35(10): 1156–1163. [PubMed: 18565198] 
Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Kuiper S, Vd 
Bergh Weerman MA, Groener JE, Poorthuis BJ, Hollak CE and Aerts JM (2010). “Plasma 
globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry 
disease.” Biochim Biophys Acta 1802(9): 741–748. [PubMed: 20471476] 
Kaissarian et al. Page 11
Mol Genet Metab. Author manuscript; available in PMC 2019 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Sanchez-Nino MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, Ruiz-Ortega 
M, Egido J and Ortiz A (2011). “Globotriaosylsphingosine actions on human glomerular 
podocytes: implications for Fabry nephropathy.” Nephrol Dial Transplant 26(6): 1797–1802. 
[PubMed: 20504837] 
Schueler UH, Kolter T, Kaneski CR, Blusztajn JK, Herkenham M, Sandhoff K and Brady RO (2003). 
“Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for 
assessing neuronal damage in Gaucher disease type 2 and 3.” Neurobiol Dis 14(3): 595–601. 
[PubMed: 14678774] 
Shaul PW, Smart J, Robinson LJ, German Z (1996). “Acylation targets endothelial nitric-oxide 
synthase to plasmalemmal caveolae.” J Biol Chem 271(11): 6518–6522 [PubMed: 8626455] 
Shu L, Murphy HS, Cooling L and Shayman JA (2005). “An in vitro model of Fabry disease.” J Am 
Soc Nephrol 16(9): 2636–2645. [PubMed: 16033856] 
Shu L, Park JL, Byun J, Pennathur S, Kollmeyer J and Shayman JA (2009). “Decreased nitric oxide 
bioavailability in a mouse model of Fabry disease.” J Am Soc Nephrol 20(9): 1975–1985. 
[PubMed: 19628671] 
Shu L and Shayman JA (2007). “Caveolin-associated accumulation of globotriaosylceramide in the 
vascular endothelium of alpha-galactosidase A null mice.” J Biol Chem 282(29): 20960–20967. 
[PubMed: 17535804] 
Shu L, Vivekanandan-Giri A, Pennathur S, Smid BE, Aerts JM, Hollak CE and Shayman JA (2014). 
“Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease.” Kidney Int 
86(1): 58–66. [PubMed: 24402087] 
Sims K, Politei J, Banikazemi M and Lee P (2009). “Stroke in Fabry Disease Frequently Occurs 
Before Diagnosis and in the Absence of Other Clinical Events: Natural History Data From the 
Fabry Registry.” Stroke 40(3): 788–794. [PubMed: 19150871] 
Smid BE, van der Tol L, Biegstraaten M, Linthorst GE, Hollak CE and Poorthuis B (2015). “Plasma 
globotriaosylsphingosine in relation to phenotypes of Fabry disease.” J Med Genet 52(4): 262–
268. [PubMed: 25596309] 
Tanaka K and Webster HD (1993). “Effects of psychosine (galactosylsphingosine) on the survival and 
the fine structure of cultured Schwann cells.” J Neuropathol Exp Neurol 52(5): 490–498. 
[PubMed: 8360702] 
Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, Ishige N, Suzuki K, Kitagawa T 
and Sakuraba H (2010). “Plasma globotriaosylsphingosine as a biomarker of Fabry disease.” Mol 
Genet Metab 100(3): 257–261. [PubMed: 20409739] 
van Breemen MJ, Rombach SM, Dekker N, Poorthuis BJ, Linthorst GE, Zwinderman AH, Breunig F, 
Wanner C, Aerts JM and Hollak CE (2011). “Reduction of elevated plasma 
globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement 
therapy.” Biochim Biophys Acta 1812(1): 70–76. [PubMed: 20851180] 
Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P and Pritchard 
KA Jr. (1998). “Superoxide generation by endothelial nitric oxide synthase: the influence of 
cofactors.” Proc Natl Acad Sci U S A 95(16): 9220–9225. [PubMed: 9689061] 
Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A, Mannens MM, 
Aerts JM and Hollak CE (2007). “The Dutch Fabry cohort: diversity of clinical manifestations and 
Gb3 levels.” J Inherit Metab Dis 30(1): 68–78. [PubMed: 17206462] 
Xia Y, Tsai AL, Berka V and Zweier JL (1998). “Superoxide generation from endothelial nitric-oxide 
synthase. A Ca2+/calmodulin-dependent and tetrahydrobiopterin regulatory process.” J Biol Chem 
273(40): 25804–25808. [PubMed: 9748253] 
Kaissarian et al. Page 12
Mol Genet Metab. Author manuscript; available in PMC 2019 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
(a) CRISPR/Cas9-modified clones 2, 5, 12, and 14 do not express Gla. Clone 17 represents 
the WT control used for all studies. (b) A representative TLC plate charred with 1% (wt/vol) 
orcinol in 11% (v/v) H2SO4 is shown. Quantification of (c) Gb4, (d) Gb3, (e) LacCer 
compared to WT control (100%, dotted line). Abbreviations: glucosylceramide (GlcCer), 
lactosylceramide (LacCer), globotriaosylceramide (Gb3), globotetraosylceramide (Gb4), 
standards (stnds). n=10 ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05
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Figure 2. 
(a) Lyso-Gb3 is elevated in CRISPR/Cas9 GLA-deficient cells compared to clone 17 (WT). 
(b) Lyso-Gb3 is elevated in 6-day anti-GLA siRNA treated cells compared to 3-day anti-
GLA siRNA treatment and 6-day scrambled-siRNA (scr) treatment. n=3. ****P<0.0001, 
***P<0.001, **P<0.01.
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Figure 3. 
(a) NO production was significantly lower in GLA-deficient cell lines, 5, 12, and 14, when 
compared to the WT control 17. n=18. (b) GLA-deficient cells have less eNOS protein 
expression. A representative Western blot from CRISPR/Cas9 clonal cell lines is shown. 
GLA-deficiency causes a decrease in eNOS expression in clone 12, but is not statistically 
significant (p=0.08). Clone 2, n=3; clones 5, 12, and 14, n=4; clone 17(WT), n=6. **P<0.01, 
****P<0.0001 compared to 17(WT)
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Figure 4. 
(a) GLA-deficient cell lines (2, 5, 12, 14) and the WT cell line (17) were treated with 
exogenous GLA (shaded bars), resulting in increased NO production. Dotted line indicates 
WT control (C) normalized to 100%. n=8. Significance shown compared to 17(WT) control. 
(b) GLA-deficient cell lines (2, 5, 12, 14) and the WT cell line (17) were treated with 
eliglustat (20 or 200 nM) for 3 days, resulting in decreased NO production. Results are 
reported as %17(WT)-vehicle. n=5. Significance shown compared to 17(WT) each 
treatment. ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05
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Figure 5. 
The NOS reaction was performed with different amounts of lyso-Gb3 in the reaction 
mixture. Each reaction contained 10 µg of protein from WT or GLA (-) lysates. (A) Lyso-
Gb3 was added to the NOS reaction mixture. (B) GlcSph was added to the NOS reaction 
mixture. Results are reported as %WT-DMSO (dotted line). n=3. ****P<0.0001, 
***P<0.001, **P<0.01, *P<0.05 compared to DMSO each cell type.
Kaissarian et al. Page 17
Mol Genet Metab. Author manuscript; available in PMC 2019 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Kaissarian et al. Page 18
Table 1.
Comparative changes in globo series glycosphingolipids and eNOS activity with siRNA and CRISPR/Cas9 
GLA deficiency.
Cell Model Gb3 Gb4 lyso-Gb3 eNOS activity
siRNA ↑↑↑ ↑ ↑↑↑ ↓↓↓
CRISPR/Cas9 -↑ ↑↑↑ ↑↑↑ ↓↓↓
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